Phase II trial of healthy-donor derived full-spectrum microbiome therapeutic MTP-101-C in steroid relapse/refractory immune-related cutaneous adverse events (ircAEs) and immune-mediated colitis (IMC) (FMT-ELIMINATE)

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.